The Pharma Letter1h
Roches licenses novel DLL3 ADC from Innovent
China’s Innovent Biologics today announced a collaboration and exclusive license agreement with Swiss pharma giant Roche to ...
The Pharma Letter4h
Kazia faces FDA setback, targets Phase III trial
Kazia Therapeutics faces a setback as the FDA deems accelerated approval for brain cancer drug paxalisib unlikely despite ...
The Pharma Letter4h
Hutchmed divests joint venture for $608 million
Hutchmed sells its 45% stake in SHPL for $608 million, aligning with its focus on oncology and immunology. Proceeds will fund ...
The Pharma Letter6h
Type 1 diabetes market to reach $9.9 billion in 7MM by 2033
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) ...
The Pharma Letter5h
IDEAYA Biosciences in-licenses Hengrui’s SHR-4849
California-based IDEAYA Biosciences has entered into an exclusive license agreement for SHR-4849, a novel DLL3-targeting Topo ...
The Pharma Letter6h
HOOKIPA Pharma in early talks to acquire Poolbeg
Austrian arenaviral technology firm HOOKIPA Pharma and Poolbeg Pharma have entered into non-binding discussions for an ...
The Pharma Letter8h
Pfizer walks away, sends Sangamo shares falling again
Pfizer ends its collaboration with Sangamo Therapeutics on a haemophilia A gene therapy despite strong Phase III results and ...
The Pharma Letter18h
New $2,000 out-of-pocket Rx drug cap takes effect in USA
The new $2,000 cap on out-of-pocket costs for prescription drugs went into effect as of January 1, 2025, the US Department of ...
The Pharma Letter18h
Verastem soars on FDA priority review for avutometinib
The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under the accelerated ...